In this article, Cerba dives into CAR+ T-cell therapy, from patient treatment to solutions for minimal residual disease (MRD) ...

MaxCyte, Inc. (NASDAQ: MXCT), a leading cell-engineering focused company, recently announced the acquisition of SeQure DX Inc., a market leader in on-target and off-target editing assessment services ...

MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing solutions to advance the discovery, development and commercialization of next-generation cell ...

Findings indicate that altering glucose metabolism in T cells boosts their therapeutic potential against melanoma, paving the way for improved immunotherapies.

In a report released today, Matt Hewitt from Craig-Hallum assigned a Buy rating to MaxCyte (MXCT – Research Report). The company’s shares ...

At Texas A&M University, one research lab is changing the game of droplet microfluidics, a technique that involves conducting ...

In this webinar, Ethan Shelkey and Aurita Menezes will highlight key aspects in the design of cell-based assays.

Roche’s PATHWAY HER2 (4B5) test helps identify patients with HER2-ultralow breast cancer, who may be eligible for targeted ...

Angle announces new results for dual analysis of CTC-DNA and ctDNA using Illumina assay and sequencing platform: London Saturday, February 1, 2025, 15:00 Hrs [IST] Angle plc, a wo ...

Scientists studying an aggressive cancer that affects thousands of dogs annually have uncovered a genetic signature that ...

Dewpoint Therapeutics’ second development candidate, DPTX3496 is an oral, small molecule acting via a novel ...